Goat anti Human IL6 polyclonal antibody [Biotin]

Purpose: One of the challenges of adoptive T-cell therapy is the development of immune-mediated toxicities including cytokine release syndrome (CRS) and neurotoxicity (NT). We aimed to identify factors that place patients at high risk of severe toxicity or treatment-related death in a cohort of 75 patients with large B-cell lymphoma treated with a standard of care CD19 targeted CAR T-cell product (axicabtagene ciloleucel). Experimental Design: Serum cytokine and catecholamine levels were measured prior to lymphodepleting chemotherapy, on the day of CAR T infusion and daily thereafter while patients remained hospitalized. Tumor biopsies were taken within 1 month prior to CAR T infusion for evaluation of gene expression. Results: We identified an association between pretreatment levels of IL6 and life-threatening CRS and NT. Because the risk of toxicity was related to pretreatment factors, we hypothesized that the tumor microenvironment (TME) may influence CAR T-cell toxicity. In pretreatment patient tumor biopsies, gene expression of myeloid markers was associated with higher toxicity. Conclusions: These results suggest that a proinflammatory state and an unfavorable TME preemptively put patients at risk for toxicity after CAR T-cell therapy. Tailoring toxicity management strategies to patient risk may reduce morbidity and mortality.

Objective Optineurin (OPTN) is an autophagy adaptor/receptor that acts as an intrinsic negative regulator of osteoclast differentiation.RANKLexpressed by rheumatoid arthritis synovial fibroblasts (RASFs) is primarily responsible for the development of bone erosions in patients withRA. The aim of the present study was to explore the role ofOPTNin the pathogenesis of joint destruction inRA. Methods RASFs were left untreated or incubated with tumor necrosis factor (TNF) or interferon-gamma (IFN gamma), and expression ofOPTNbyRASFs was analyzed by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and Western blotting. Expression ofRANKLand osteoprotegerin (OPG) was evaluated in cultures ofOPTN-reducedRASFs with or withoutTNForIFN gamma treatment.OPTN-reducedRASFs were cocultured with monocytes and stained for tartrate-resistant acid phosphatase (TRAP). I kappa B alpha,NF-kappa B1, and RelA protein levels were measured to evaluateNF-kappa B signaling. Expression of messengerRNA(mRNA) for matrix metalloproteinase 3 (MMP3), interleukin-6 (IL6),GATAbinding protein 3 (GATA3), carbohydrate sulfotransferase 15 (CHST15), hyaluronan synthase 1 (HAS1), andGATA1was analyzed byRT-qPCR. Results InRASFs incubated withTNForIFN gamma,OPTNexpression was up-regulated andRANKLexpression was increased, and these effects were further pronounced inOPTN-reducedRASFs (allP< 0.05 versus controls).OPG mRNAlevels remained unchanged. Monocytes cocultured withOPTN-reducedRASFs differentiated to a greater extent intoTRAP+ multinucleated cells compared to monocytes cocultured with controlRASFs (P< 0.05). I kappa B alpha degradation and nuclearNF-kappa B1 expression followingTNFtreatment were both prolonged inOPTN-reducedRASFs (eachP< 0.05 versus controls).MMP3mRNAlevels were up-regulated, whileGATA3,CHST15, andHAS1mRNAlevels were down-regulated inOPTN-reducedRASFs (eachP< 0.05 versus controls). Conclusion OPTNplays a protective role inRAwhen it is up-regulated inRASFs in the presence of proinflammatory cytokines. Absence ofOPTNmight worsenRAby generating a joint-destructive state, as indicated by evidence of increasedRANKLexpression onRASFs and subsequent osteoclast differentiation.